Emphysema Treatment, page-2

They were a big player 10 years ago, but would not think they would get their fingers burnt twice.
Google Bioxyne report from December 2013 and this will explain.
Basically when they were called Hunter Immunology they were developing a COPD vaccine.
First clinical trial (38 patients) went really really well. Second clinical trial (300 patients) crashed badly.
This was partially explained by the mildest winter in Sydney for 20 years when the trial took place. COPD is worst in winter months.
End result their share price went from 26c to 2c, sold Hunter Immunology (called Probiomics at the time) which included all their
intellectual property to Mariposa Health Care. Received some cash at the time and also a small percentage of future profits if the vaccine was developed to market successfully.